Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?

As part of a cluster of articles leading up to the 2012 World Health Report and critically reflecting on the theme of “no health without research,” Suerie Moon and colleagues argue for a global health R&D treaty to improve innovation in new medicines and strengthening affordability, sustainable financing, efficiency in innovation, and equitable health-centered governance.

[1]  M. Price,et al.  Prizes and Parasites: Incentive Models for Addressing Chagas Disease , 2009, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[2]  D. Bradley.  The Commission on Health Research for Development. , 1989, The Journal of tropical medicine and hygiene.

[3]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.

[4]  O. Razum,et al.  Expert Delphi survey on research and development into drugs for neglected diseases , 2011, BMC health services research.

[5]  E. Berndt,et al.  Advance Market Commitment for Pneumococcal Vaccines: Putting Theory into practice/Engagement Prealable Relatif Au Marche Pour Les Vaccins Contre le Pneumocoque: Mettre la Theorie En pratique/Compromiso De Mercado Avanzado Para Vacunas Neumococicas: Poniendo En Practica la Teoria , 2011 .

[6]  J. Guzman,et al.  Neglected disease research and development: Is innovation under threat? , 2011 .

[7]  T. Sabanna.  Intellectual Property Rights in WTO and Developing Countries , 2010 .

[8]  Prizes for innovation of new medicines and vaccines. , 2009, Annals of health law.

[9]  Ada Verloren.  The United Nations Children's Fund , 2009 .

[10]  Nedjeljko Frančula.  The National Academies Press , 2013 .

[11]  A. Banerjee,et al.  The Health Impact Fund: incentives for improving access to medicines , 2010, The Lancet.

[12]  Suerie Moon,et al.  Driving a decade of change: HIV/AIDS, patents and access to medicines for all , 2011, Journal of the International AIDS Society.

[13]  Jyoti Yadav,et al.  Open Source Drug Discovery , 2008 .

[14]  R. McConkey.  Health Research: Essential Link to Equity in Development , 1992 .

[15]  CONSTITUTION of the World Health Organization. , 1947, Chronicle of the World Health Organization.

[16]  D. Light,et al.  Demythologizing the high costs of pharmaceutical research , 2011 .

[17]  T. Cymet,et al.  The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .

[18]  Peter Temin,et al.  Reasonable Rx: Solving the Drug Price Crisis , 2008 .

[19]  John Braithwaite,et al.  Information Feudalism: Who Owns the Knowledge Economy? , 2002 .

[20]  Haym Benaroya.  Science and commerce , 2010 .

[21]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[22]  J. Travis.  Prizes Eyed to Spur Medical Innovation , 2008, Science.

[23]  John Travis.  Science by the Masses , 2008, Science.

[24]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[25]  B. Munos,et al.  Can Open‐Source Drug R&D Repower Pharmaceutical Innovation? , 2010, Clinical pharmacology and therapeutics.

[26]  Joshua Lerner,et al.  Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It , 2011 .

[27]  Mary Moran,et al.  A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need , 2005, PLoS Medicine.

[28]  Marlynn H Wei.  Should Prizes Replace Patents? A Critique of the Medical Innovation Prize Act of 2005 , 2007 .

[29]  Organización Mundial de la Salud.  Global strategy and plan of action on public health, innovation and intellectual property , 2009 .

[30]  J. Watal.  Intellectual property rights in the WTO and developing contries , 2001 .

[31]  H. Nikogosian.  WHO Framework Convention on Tobacco Control: a key milestone. , 2010, Bulletin of the World Health Organization.

[32]  N. Ford,et al.  The Courage to Change the Rules: A Proposal for an Essential Health R&D Treaty , 2005, PLoS medicine.

[33]  J. DiMasi,et al.  Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 , 2011, Clinical pharmacology and therapeutics.

[34]  Susan K. Sell.  Private Power, Public Law: The Globalization of Intellectual Property Rights , 2003 .

[35]  Colin W. Binns,et al.  Health Research-Essential Link to Equity in Development , 1990 .

[36]  Tim Hubbard,et al.  A New Trade Framework for Global Healthcare R&D , 2004, PLoS biology.

[37]  Inge Kaul,et al.  Global Public Goods: International Cooperation in the 21st Century , 1999 .

[38]  J. DiMasi,et al.  Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D , 2004 .

[39]  S. Harman.  Global Health Governance , 2012 .

[40]  D. Kynaston,et al.  Financial times , 2024, Nursery World.

[41]  J. Bermudez,et al.  The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good , 2010, The open AIDS journal.

[42]  M. Mogee,et al.  Global dimensions of intellectual property rights in science and technology , 1993 .

[43]  Stephanie Strom,et al.  Drug maker's vow to donate cancer medicine falls short. , 2003, The New York times on the Web.

[44]  Richard Cash,et al.  Health as a Global Public Good , 1999 .

[45]  D. Butler.  Vaccine offers meningitis hope , 2010, Nature.

[46]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[47]  Keith E. Maskus,et al.  Integrating Intellectual Property Rights and Development Policy: Report of the Commission on Intellectual Property Rights, Commission on Intellectual Property Rights September 2002 , 2004 .